- KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025
-
Sohn W, Lee YS, Kim SS, Kim JH, Jin YJ, Kim GA, Sung PS, Yoo JJ, Chang Y, Lee EJ, Lee HW, Choi M, Yu SJ, Jung YK, Jang BK, on behalf of The Korean Association for the Study of the Liver (KASL)
- KMID: 2565369
- Clin Mol Hepatol.
- 2025 Feb;31(Suppl):S1-S31.
- doi: 10.3350/cmh.2025.0045
-
- CITED
-
- Close
- SHARE
-
- Close
- Liver organoids: Current advances and future applications for hepatology
-
Kim Y, Kang M, Mamo MG, Adisasmita M, Huch M, Choi D
- KMID: 2565384
- Clin Mol Hepatol.
- 2025 Feb;31(Suppl):S327-S348.
- doi: 10.3350/cmh.2024.1040
The creation of self-organizing liver organoids represents a significant, although modest, step toward addressing the ongoing organ shortage crisis in allogeneic liver transplantation. However, researchers have recognized that achieving a... -
- CITED
-
- Close
- SHARE
-
- Close
- Liquid biopsy in hepatocellular carcinoma: Challenges, advances, and clinical implications
-
Park J, Lee YT, Agopian VG, Liu JS, Koltsova EK, You S, Zhu Y, Tseng HR, Yang JD
- KMID: 2565381
- Clin Mol Hepatol.
- 2025 Feb;31(Suppl):S255-S284.
- doi: 10.3350/cmh.2024.0541
Hepatocellular carcinoma (HCC) is an aggressive primary liver malignancy often diagnosed at an advanced stage, resulting in a poor prognosis. Accurate risk stratification and early detection of HCC are critical... -
- CITED
-
- Close
- SHARE
-
- Close
- Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease
-
Wang Y, Song SJ, Jiang Y, Lai JCT, Wong GLH, Wong VWS, Yip TCF
- KMID: 2565371
- Clin Mol Hepatol.
- 2025 Feb;31(Suppl):S51-S75.
- doi: 10.3350/cmh.2024.0246
In managing metabolic dysfunction-associated steatotic liver disease, which affects over 30% of the general population, effective noninvasive biomarkers for assessing disease severity, monitoring disease progression, predicting the development of liver-related... -
- CITED
-
- Close
- SHARE
-
- Close
- Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease
-
Saeed H, Díaz LA, Gil-Gómez A, Burton J, Bajaj JS, Romero-Gomez M, Arrese M, Arab JP, Khan MQ
- KMID: 2565373
- Clin Mol Hepatol.
- 2025 Feb;31(Suppl):S94-S111.
- doi: 10.3350/cmh.2024.0811
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a significant global health issue, affecting over 30% of the population worldwide due to the rising prevalence of metabolic risk factors such as... -
- CITED
-
- Close
- SHARE
-
- Close
- Prospect of emerging treatments for hepatitis B virus functional cure
-
Hui RWH, Mak LY, Fung J, Seto WK, Yuen MF
- KMID: 2565376
- Clin Mol Hepatol.
- 2025 Feb;31(Suppl):S165-181.
- doi: 10.3350/cmh.2024.0855
Functional cure, defined as sustained hepatitis B surface antigen (HBsAg) seroclearance with unquantifiable hepatitis B virus (HBV) DNA at 24 weeks off treatment, is a favorable treatment endpoint in chronic... -
- CITED
-
- Close
- SHARE
-
- Close
- Prediction and prevention of post-procedural bleedings in patients with cirrhosis
-
Riescher-Tuczkiewicz A, Rautou PE
- KMID: 2565379
- Clin Mol Hepatol.
- 2025 Feb;31(Suppl):S205-S227.
- doi: 10.3350/cmh.2024.0928
Although post-procedural bleedings are infrequent in patients with cirrhosis, they are associated with significant morbidity and mortality. Therefore, predicting and preventing such bleedings is important. Established predictors of post-procedural bleeding... -
- CITED
-
- Close
- SHARE
-
- Close
- Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0
-
Wu D, Kao JH, Piratvisuth T, Wang X, Kennedy PT, Otsuka M, Ahn SH, Tanaka Y, Wang G, Yuan Z, Li W, Lim YS, Niu J, Lu F, Zhang W, Gao Z, Kaewdech A, Han M, Yan W, Ren H, Hu P, Shu S, Kwo PY, Wang Fs, Yuen MF, Ning Q
- KMID: 2565375
- Clin Mol Hepatol.
- 2025 Feb;31(Suppl):S134-S164.
- doi: 10.3350/cmh.2024.0780
As new evidence emerges, treatment strategies toward the functional cure of chronic hepatitis B are evolving. In 2019, a panel of national hepatologists published a Consensus Statement on the functional... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
-
Hwang SY, Danpanichkul P, Agopian V, Mehta N, Parikh ND, Abou-Alfa GK, Singal AG, Yang JD
- KMID: 2565380
- Clin Mol Hepatol.
- 2025 Feb;31(Suppl):S228-S254.
- doi: 10.3350/cmh.2024.0824
Hepatocellular carcinoma (HCC) is a major global burden, ranking as the third leading cause of cancer-related mortality. HCC due to chronic hepatitis B virus (HBV) or C virus (HCV) infection... -
- CITED
-
- Close
- SHARE
-
- Close
- Prediction and management of small-for-size syndrome in living donor liver transplantation
-
Law Jh, Kow AWC
- KMID: 2565383
- Clin Mol Hepatol.
- 2025 Feb;31(Suppl):S301-S326.
- doi: 10.3350/cmh.2024.0870
Small-for-size syndrome (SFSS) remains a critical challenge in living donor liver transplantation (LDLT), characterized by graft insufficiency due to inadequate liver volume, leading to significant postoperative morbidity and mortality. As... -
- CITED
-
- Close
- SHARE
-
- Close
- Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B
-
Zhang S, Mak LY, Yuen MF, Seto WK
- KMID: 2565377
- Clin Mol Hepatol.
- 2025 Feb;31(Suppl):S182-S195.
- doi: 10.3350/cmh.2024.0837
Chronic hepatitis B (CHB) poses a major global public health challenge and is a leading cause of cirrhosis and liver cancer. Hepatic steatosis is common in individuals with CHB compared... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis E as a trigger for acute-on-chronic liver failure
-
Buti M, Ruiz-Cobo JC, Esteban R, Riveiro-Barciela M
- KMID: 2565378
- Clin Mol Hepatol.
- 2025 Feb;31(Suppl):S196-S204.
- doi: 10.3350/cmh.2024.0758
Acute hepatitis E virus (HEV) infection is typically self-limiting and has a favourable prognosis. However, certain populations such as patients with pre-existing chronic liver disease may experience severe manifestations, including... -
- CITED
-
- Close
- SHARE
-
- Close
- Alcohol-associated liver disease: Natural history, management and novel targeted therapies
-
Alvarado-Tapias E, Pose E, Gratacós-Ginès J, Clemente-Sánchez A, López-Pelayo H, Bataller R
- KMID: 2565374
- Clin Mol Hepatol.
- 2025 Feb;31(Suppl):S112-S133.
- doi: 10.3350/cmh.2024.0709
Alcohol consumption is a leading cause of preventable morbidity and mortality worldwide and the primary cause of advanced liver disease. Alcohol use disorder is a chronic, frequently relapsing condition characterized... -
- CITED
-
- Close
- SHARE
-
- Close
- Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation
-
Sha M, Wang J, Cao J, Zou ZH, Qu Xy, Xi Zf, Shen C, Tong Y, Zhang Jj, Jeong S, Xia Q
- KMID: 2565382
- Clin Mol Hepatol.
- 2025 Feb;31(Suppl):S285-S300.
- doi: 10.3350/cmh.2024.0323
Hepatocellular carcinoma (HCC) is a leading cause of cancer-associated death globally. Liver transplantation (LT) has emerged as a key treatment for patients with HCC, and the Milan criteria have been... -
- CITED
-
- Close
- SHARE
-
- Close
- Epidemiology of metabolic dysfunction-associated steatotic liver disease
-
Younossi ZM, Kalligeros M, Henry L
- KMID: 2565370
- Clin Mol Hepatol.
- 2025 Feb;31(Suppl):S32-S50.
- doi: 10.3350/cmh.2024.0431
As the rates of obesity and type 2 diabetes (T2D) continue to increase globally, so does the prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD). Currently, 38% of all adults... -
- CITED
-
- Close
- SHARE
-
- Close
- Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease
-
Caddeo A, Romeo S
- KMID: 2565372
- Clin Mol Hepatol.
- 2025 Feb;31(Suppl):S76-S93.
- doi: 10.3350/cmh.2024.0438
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a complex multifactorial disease and becoming the leading cause of liver-related morbidity and mortality. MASLD spans from isolated steatosis to metabolic dysfunction-associated steatohepatitis... -
- CITED
-
- Close
- SHARE
-
- Close
